Decisions on Further Research for Predictive Biomarkers of High-Dose Alkylating Chemotherapy in Triple-Negative Breast Cancer: A Value of Information Analysis

Abstract Objectives To inform decisions about the design and priority of further studies of emerging predictive biomarkers of high-dose alkylating chemotherapy (HDAC) in triple-negative breast cancer (TNBC) using value-of-information analysis. Methods A state transition model compared treating women...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Value in health 2016-06, Vol.19 (4), p.419-430
Hauptverfasser:	Miquel-Cases, Anna, MPharm, MSc, Retèl, Valesca P., PhD, van Harten, Wim H., MD, PhD, Steuten, Lotte M.G., PhD
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Alkylating Agents - economics Alkylating Agents - therapeutic use Antineoplastic Agents - economics Antineoplastic Agents - therapeutic use Biomarkers, Tumor - economics Cost-Benefit Analysis decision modeling Decision Support Techniques diagnostics Disease-Free Survival Female Health Priorities - economics high-dose alkylating chemotherapy Humans Internal Medicine Markov Chains Middle Aged Netherlands - epidemiology predictive biomarkers Randomized Controlled Trials as Topic Research - economics RNA, Long Noncoding Triple Negative Breast Neoplasms - drug therapy Triple Negative Breast Neoplasms - economics Triple Negative Breast Neoplasms - epidemiology Triple Negative Breast Neoplasms - therapy Tumor Suppressor p53-Binding Protein 1 Ubiquitin-Protein Ligases - economics Ubiquitin-Protein Ligases - genetics value of information
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!